Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes

Pharmacogenomics

Volumn 13, Issue 1, 2012, Pages 31-41

  Hein, David W ^a   Doll, Mark A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Acetylator genotype; Acetylator phenotype; Cryopreserved; Human hepatocyte; NAT2; SNP

Indexed keywords

ACYLTRANSFERASE; ADENINE; ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; CYTOSINE; GUANINE; SULFADIMIDINE; THYMINE;

ACCURACY; ACETYLATOR PHENOTYPE; AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; HUMAN CELL; LIVER CELL; NAT2 GENE; PACIFIC ISLANDER; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; CATALYSIS; ETHNIC GROUPS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPATOCYTES; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; UNITED STATES;

EID: 83755195441     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.122     Document Type: Article

References (51)

1. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485-491 (1960).
2. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol. Rev. 37, 25-79 (1985). (Pubitemid 15081093)
3. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Muller A, Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev. 31, 489-502 (1999). (Pubitemid 29222674)
4. Blum M, Demierre A, Grant DM, Heim, M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl Acad. Sci. USA 88, 5237-5241 (1991). (Pubitemid 21914719)
5. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl Acad. Sci. USA 88, 6333-6337 (1991). (Pubitemid 21914940)
6. Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab. Rev. 37, 511-564 (2005). (Pubitemid 41434161)
7. Grant DM, Goodfellow GH, Sugamori K, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 61, 204-211 (2000).
8. Sim E, Lack N, Wang CJ et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 254, 170-183 (2008).
9. Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9, 29-42 (2000). (Pubitemid 30062907)
10. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab. 9, 520-531 (2008). (Pubitemid 352025183)
11. Walraven JM, Zang Y, Trent JO, Hein DW. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr. Drug Metab. 9, 471-486 (2008). (Pubitemid 352025179)
12. Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin. Drug Metab. Toxicol. 5, 353-366 (2009).
13. Deitz AC, Rothman N, Rebbeck TR et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol. Biomarkers Prev. 13, 1543-1546 (2004). (Pubitemid 39202325)
14. Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal. Biochem. 231, 413-420 (1995).
15. Rothman N, Garcia-Closas M, Chatterjee N et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42, 978-984 (2010).
16. Garcia-Closas M, Hein DW, Silverman D et al. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet. Genomics 21, 231-236 (2011).
17. Doll MA, Zang Y, Moeller T, Hein DW. Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. J. Pharmacol. Exp. Ther. 334, 540-544 (2010).
18. Doll MA, Hein, DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal. Biochem. 288, 106-108 (2001). (Pubitemid 32047653)
19. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658 (2006).
20. Leff MA, Epstein PN, Doll MA et al. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther. 290, 182-187 (1999). (Pubitemid 29302318)
21. Chapron DJ, Kramer PA, Mercik SA. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin. Pharmacol. Ther. 27, 104-113 (1980). (Pubitemid 10128549)
22. Chen B, Zhang WX, Cai WM. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur. J. Clin. Pharmacol. 62, 355-359 (2006).
23. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265, 12757-12760 (1990). (Pubitemid 20234207)
24. Parkin DP, Vandenplas S, Botha FJ et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155, 1717-1722 (1997). (Pubitemid 27216683)
25. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J. Med. Genet. 34, 758-760 (1997). (Pubitemid 27406199)
26. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49, 1733-1738 (2005). (Pubitemid 40631582)
27. Ma JJ, Liu CG, Li JH, Cao XM, Sun SL, Yao X. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin. Chim. Acta 407, 30-35 (2009).
28. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 17, 459-464 (1984). (Pubitemid 14055277)
29. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57, 581-592 (1995).
30. Hein DW, Trinidad A, Yerokun T, Ferguson RJ, Kirlin WG, Weber WW. Genetic control of acetyl coenzyme A-dependent arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, A/J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse. Drug Metab. Dispos. 16, 341-347 (1988).
31. Hein DW, Rustan TD, Bucher KD, Miller LS. Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian-hamsters congenic at the polymorphic acetyltransferase locus. J. Pharmacol. Exp. Ther. 259, 699-704 (1991).
32. Hein DW, Doll MA, Rustan TD, Gray K, Ferguson RJ, Feng Y. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Toxicol. Appl. Pharmacol. 124, 16-24 (1994). (Pubitemid 24079030)
33. Hein DW, Rustan TD, Bucher KD, Martin WJ, Furman EJ. Acetylator phenotype-dependent and -independent expression of arylamine N-acetyltransferase isozymes in rapid and slow acetylator inbred rat liver. Drug Metab. Dispos. 19, 933-937 (1991).
34. Hein DW, Bendaly J, Neale JR, Doll MA. Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat. Drug Metab. Dispos. 36, 2452-2459 (2008).
35. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 39, 184-191 (1991).
36. Hein DW, Doll MA, Rustan TD et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14, 1633-1638 (1993). (Pubitemid 23249371)
37. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet. 3, 729-734 (1994). (Pubitemid 24148616)
38. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 55, 3531-3536 (1995).
39. Grant DM, Hughes NC, Janezic SA et al. Human acetyltransferase polymorphisms. Mutat. Res. 376, 61-70 (1997).
40. Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11, 207-215 (2001). (Pubitemid 32319870)
41. Hein DW, Fretland AJ Doll MA. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int. J. Cancer 119, 1208-1211 (2006). (Pubitemid 44116930)
42. Zang Y, Zhao S, Doll MA, States JC, Hein DW. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14, 717-723 (2004). (Pubitemid 39552786)
43. Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 28, 1665-1671 (2007). (Pubitemid 47289027)
44. Selinski S, Blaszkewicz M, Lehmann ML et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet. Genomics 21(10), 673-678 (2011).
45. Loktionov A, Moore W, Spencer SP et al. Differences in N-acetylation genotypes between Caucasians and black South Africans: implications for cancer prevention. Cancer Detect. Prev. 26, 15-22 (2002). (Pubitemid 36087177)
46. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 9, 21 (2008).
47. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: A worldwide population survey. PLoS ONE 6, e18507 (2011).
48. Ohno M, Yamaguchi I, Yamamoto I et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4, 256-261 (2000). (Pubitemid 30151575)
49. Hiratsuka M, Kishikawa Y, Takekuma Y et al. Genotyping of the N-acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab. Pharmacokinet. 17, 357-362 (2002).
50. Cho HJ, Koh WJ, Ryu YJ et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87, 551-556 (2007).
51. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 7071-7073 (2010).